CURIS INC: Nantahala Capital Partners Limited Partnership amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Nantahala Capital Partners Limited Partnership amended its Schedule 13G stake filing for Curis Inc., disclosing the change to the SEC under accession number 0001104659-26-127115. The filing updates the investment firm's previously reported beneficial ownership position in the clinical-stage oncology drug developer. Schedule 13G amendments are typically filed when a passive investor's stake crosses or adjusts past the 5% reporting threshold, making the disclosure a signal of shifting institutional interest in the small-cap biotech. The amended filing did not specify a revised share count or percentage in the headline disclosure. Investors will watch for further 13G or 13D filings to gauge whether Nantahala is building or trimming its position in Curis.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
CURIS INC, Nantahala Capital Partners Limited Partnership